Literature DB >> 16234483

A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.

Karen M King1, Vijaya L Damaraju, Mark F Vickers, Sylvia Y Yao, Thach Lang, Tracey E Tackaberry, Delores A Mowles, Amy M L Ng, James D Young, Carol E Cass.   

Abstract

2-Chloro-9-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)adenine (Cl-F-ara-A, clofarabine), a purine nucleoside analog with structural similarity to 2-chloro-2'-deoxyadenosine (Cl-dAdo, cladribine) and 9-beta-d-arabinofuranosyl-2-fluoroadenine (F-ara-A, fludarabine), has activity in adult and pediatric leukemias. Mediated transport of the purine nucleoside analogs is believed to occur through the action of two structurally unrelated protein families, the equilibrative nucleoside transporters (ENTs) and the concentrative nucleoside transporters (CNTs). The current work assessed the transportability of Cl-F-ara-A, Cl-dAdo, and F-ara-A in cultured human leukemic CEM cells that were either nucleoside transport-defective or possessed individual human nucleoside transporter types and in Xenopus laevis oocytes and Saccharomyces cerevisiae yeast that produced individual recombinant human nucleoside transporter types. Cells producing hENT1 or hCNT3 exhibited the highest uptake of Cl-F-ara-A, whereas nucleoside transport-deficient cells and cells producing hCNT1 lacked uptake altogether. When Cl-F-ara-A transport rates by hENT1 were compared with those of Cl-dAdo and F-ara-A, Cl-dAdo had the highest efficiency of transport, although Cl-F-ara-A showed the greatest accumulation during 5-min exposures. In cytotoxicity studies with the CEM lines, Cl-F-ara-A was more cytotoxic to cells producing hENT1 than to the nucleoside transport-deficient cells. The efficiency of Cl-F-ara-A transport by oocytes with recombinant transporters was hCNT3 > hENT2 > hENT1 > hCNT2; no transport was observed with hCNT1. Affinity studies with recombinant transporters produced in yeast showed that hENT1, hENT2, and hCNT3 all had higher affinities for Cl-F-ara-A than for either Cl-dAdo or F-ara-A. These results suggest that the nature and activity of the plasma membrane proteins capable of inward transport of nucleosides are important determinants of Cl-F-ara-A activity in human cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234483     DOI: 10.1124/mol.105.015768

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

2.  Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.

Authors:  Yogesh T Patel; Megan O Jacus; Nidal Boulos; Jason D Dapper; Abigail D Davis; Pradeep K Vuppala; Burgess B Freeman; Kumarasamypet M Mohankumar; Stacy L Throm; Richard J Gilbertson; Clinton F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2015-02-28       Impact factor: 3.333

Review 3.  Equilibrative nucleoside transporters-A review.

Authors:  Rebba C Boswell-Casteel; Franklin A Hays
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-10-19       Impact factor: 1.381

4.  Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors.

Authors:  Kazuya Tatani; Masahiro Hiratochi; Yoshinori Nonaka; Masayuki Isaji; Satoshi Shuto
Journal:  ACS Med Chem Lett       Date:  2015-01-28       Impact factor: 4.345

5.  Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.

Authors:  Nobuko Hijiya; Blythe Thomson; Michael S Isakoff; Lewis B Silverman; Peter G Steinherz; Michael J Borowitz; Richard Kadota; Todd Cooper; Violet Shen; Gary Dahl; Jaideep V Thottassery; Sima Jeha; Kelly Maloney; Jo-Anne Paul; Elly Barry; William L Carroll; Paul S Gaynon
Journal:  Blood       Date:  2011-10-03       Impact factor: 22.113

Review 6.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

7.  Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.

Authors:  Mazin A Moufarij; Deepa Sampath; Michael J Keating; William Plunkett
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

8.  [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.

Authors:  Woosuk Kim; Thuc M Le; Liu Wei; Soumya Poddar; Jimmy Bazzy; Xuemeng Wang; Nhu T Uong; Evan R Abt; Joseph R Capri; Wayne R Austin; Juno S Van Valkenburgh; Dalton Steele; Raymond M Gipson; Roger Slavik; Anthony E Cabebe; Thotsophon Taechariyakul; Shahriar S Yaghoubi; Jason T Lee; Saman Sadeghi; Arnon Lavie; Kym F Faull; Owen N Witte; Timothy R Donahue; Michael E Phelps; Harvey R Herschman; Ken Herrmann; Johannes Czernin; Caius G Radu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

9.  Genetic and epigenetic variants contributing to clofarabine cytotoxicity.

Authors:  Michael T Eadon; Heather E Wheeler; Amy L Stark; Xu Zhang; Erika L Moen; Shannon M Delaney; Hae Kyung Im; Patrick N Cunningham; Wei Zhang; M Eileen Dolan
Journal:  Hum Mol Genet       Date:  2013-05-29       Impact factor: 6.150

10.  Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance.

Authors:  Kristie D Ibarra; Julie K Pfeiffer
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.